ArticleJHEP reports : innovation in hepatology2021
Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness.
Article in JHEP reports : innovation in hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- IMAT-HCC model: Liver stiffness-enhanced integrated risk stratification for HCC recurrence after resection.JHEP reports : innovation in hepatology · 2026Article
- A Comparative Study of Radiofrequency Ablation, Microwave Ablation, and Percutaneous Ethanol Injection in Treatment of Hepatocellular Carcinoma-A Single-Center Experience.Diagnostics (Basel, Switzerland) · 2025Article
- Liver Elastography Methods for Diagnosis of De Novo and Recurrent Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2025Review
- Role of Spleen Stiffness Measurements with 2D Shear-Wave Elastography for Esophageal Varices in Patients with Compensated Advanced Chronic Liver Disease.Diagnostics (Basel, Switzerland) · 2025Article
- Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2025Review
- The Role of Liver Stiffness Measurement and Spleen Stiffness Measurement in Predicting the Risk of Developing HCC.Diagnostics (Basel, Switzerland) · 2024Article
- Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on "Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication".Clinical and molecular hepatology · 2024Article
- Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong.BMC gastroenterology · 2024Article
- Spleen stiffness measurement as a non-invasive assessment in patients with portal hypertension.eGastroenterology · 2024Review
- Noninvasive Fibrosis Assessment in Chronic Hepatitis C Infection: An Update.Journal of clinical and translational hepatology · 2023Review
- Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals.Journal of clinical medicine · 2023Review
- Liver function indicators and risk of hepatocellular carcinoma: a bidirectional mendelian randomization study.Frontiers in genetics · 2023Article
- Application of Ultrasound Elastography in Assessing Portal Hypertension.Diagnostics (Basel, Switzerland) · 2022Review
- Sarcopenia Predicts Major Complications after Resection for Primary Hepatocellular Carcinoma in Compensated Cirrhosis.Cancers · 2022Article
- Combined Liver Stiffness and Α-fetoprotein Further beyond the Sustained Virologic Response Visit as Predictors of Long-Term Liver-Related Events in Patients with Chronic Hepatitis C.Canadian journal of gastroenterology & hepatology · 2022Article
- Spleen Stiffness: The "New Kid on the Block" in the Diagnosis of Clinical Significant Portal Hypertension.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsHepatitis C virus (HCV) eradication with direct-acting antivirals (DAAs) reduces but does not eliminate the risk for hepatocellular carcinoma (HCC). The development of surveillance strategies for HCC after the sustained virologic response (SVR) is therefore warranted. We aimed to evaluate the role of spleen stiffness measurement (SSM) in the prediction of HCC risk in a cohort of patients with advanced chronic liver disease (ACLD) treated with DAAs.
methodsThis is a retrospective cohort study of 140 patients with HCV-related ACLD successfully treated with DAAs in our centre between 2015 and 2017. Patients with available liver stiffness (LSM) and SSM before treatment and 6 months after (SVR24) were included. A Cox regression model investigated the association between SSM and HCC development.
resultsDuring a median follow-up of 41.5 (IQR 32-49) months, 20 patients presented with HCC. SSM at SVR24 predicted HCC development in univariate and adjusted multivariate analysis (hazard ratio: 1.025; 95% CI: 1.001-1.050); the best cut-off was 42 kPa. Patients with LSM-SVR24 ≤10 kPa were at the lowest risk of HCC. In patients with LSM-SVR24 >10 kPa, HCC incidence was not further influenced by LSM values (10-20 kPa
conclusionsPortal hypertension, as evaluated by SSM, plays a significant role in liver carcinogenesis after DAA treatment. We proposed a new algorithm based on post-treatment values of LSM and SSM for the stratification of HCC risk after SVR achievement. LAY SUMMARY: Spleen stiffness predicts the development of hepatocellular carcinoma after viral eradication, especially in patients with post-treatment liver stiffness values >10 kPa. An algorithm based on liver and spleen stiffness can stratify for the risk of liver cancer development and guide the surveillance strategies after treatment with direct-acting antivirals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.